US Oncology/McKesson Specialty Health, 10101 Woodloch Forest, The Woodlands, TX 77380, USA.
Pfizer Oncology, Pfizer Inc, 235 East 42nd St., New York, NY 10017, USA.
Future Oncol. 2017 Jun;13(15):1323-1332. doi: 10.2217/fon-2016-0566. Epub 2017 May 9.
To study patient characteristics and treatment patterns in real-world axitinib use for metastatic renal cell carcinoma.
PATIENTS & METHODS: We conducted a retrospective analysis of second- or third-line axitinib use between 1 January 2012 and 31 October 2014 in 135 metastatic renal cell carcinoma patients using the US Oncology Network database.
Overall, 86.7% had clear cell histology, 57.8% had stage III/IV disease at diagnosis and 55.6% were poor risk by Heng criteria. Median treatment duration was 4.6 months (range: 0.03-35.49); 80.7% initiated axitinib at 5 mg/day twice daily, and 67.4% maintained this dose. Overall, 77.8% discontinued treatment, mainly due to disease progression (50.5%) and toxicity (21.9%).
Axitinib usage patterns were consistent with the National Comprehensive Cancer Network Guidelines. Ease of use among community oncologists and patient tolerance are key features of axitinib.
研究阿昔替尼在转移性肾细胞癌的真实世界应用中的患者特征和治疗模式。
我们使用美国肿瘤网络数据库，对 2012 年 1 月 1 日至 2014 年 10 月 31 日期间二线或三线使用阿昔替尼的 135 例转移性肾细胞癌患者进行了回顾性分析。
总体而言，86.7%的患者组织学类型为透明细胞癌，57.8%的患者诊断时为 III/IV 期疾病，55.6%的患者根据 Heng 标准为高危。中位治疗持续时间为 4.6 个月（范围：0.03-35.49）；80.7%的患者起始剂量为 5mg/天，每日两次，67.4%的患者维持该剂量。总体而言，77.8%的患者停止治疗，主要原因是疾病进展（50.5%）和毒性（21.9%）。
阿昔替尼的使用模式与国家综合癌症网络指南一致。社区肿瘤学家使用方便和患者耐受是阿昔替尼的关键特征。
